mdr-positive

Thiocolchicine is an effective inhibitor of tubulin polymerization with an IC50 of 2.5 µM and a Ki of 0.7 µM. Thiocolchicine induces cell apoptosis. Thiocolchicine can be used as an ADC cytotoxin in ADC technology.

Antibacterial agent 106 (compound 8) is a highly effective orally active antibacterial compound with antibiofilm activity, demonstrating potent antibacterial effects against multi-drug resistant (MDR) Gram-positive pathogens, including the eradication of 99.7% of intracellular methicillin-resistant S. aureus (MRSA) harbored within macrophages [1].

MDP1, derived from Melittin, disrupts the membrane integrity of both Gram-positive and Gram-negative bacteria, leading to bacterial death through membrane damage. This compound exhibits potent antibacterial activity against multidrug-resistant (MDR) and reference strains of S. aureus, E. coli, and P. aeruginosa [1].

MDP1 acetate, a derivative of Melittin, compromises the membrane integrity of both Gram-positive and Gram-negative bacteria leading to bacterial death through membrane damage. It exhibits potent antibacterial activity against multidrug-resistant (MDR) and reference strains of S. aureus, E. coli, and P. aeruginosa [1].

Lynronne-1, an antimicrobial peptide, exhibits activity against Gram-positive bacteria, including multi-drug resistant (MDR) strains, with a minimal inhibitory concentration (MIC) of 8-32 μg/mL for methicillin-resistant MRSA strains. Additionally, it effectively reduces the bacterial load in a murine model of MRSA-infected wounds and demonstrates efficacy against P. aeruginosa infections [1].

Lynronne-2, an antimicrobial peptide, exhibits activity against Gram-positive bacteria, including methicillin-resistant MRSA strains (MIC: 32-256 μg/mL), and demonstrates effectiveness in combating P. aeruginosa infections [1].

Lynronne-3, an antimicrobial peptide, demonstrates activity against Gram-positive bacteria, including multi-drug resistant (MDR) strains, with a minimum inhibitory concentration (MIC) ranging from 32-128 μg/mL for methicillin-resistant Staphylococcus aureus (MRSA) strains. Additionally, Lynronne-3 is efficacious in combating Pseudomonas aeruginosa infections [1].

Cinerubin R exhibits activity against Gram-positive bacteria and inhibits tumor cell activity, showing equivalent inhibitory effects on multidrug-resistant (MDR) cells and parent cells.